{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:57:30Z","timestamp":1782741450899,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Gennova Biopharmaceuticals Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40123-026-01414-0","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:39:17Z","timestamp":1780497557000},"page":"2487-2499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of GBL1204\u2014An Ophthalmic Bevacizumab in Prefilled Syringe for Neovascular Age-Related Macular Degeneration: A Phase\u00a0I Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Amit","family":"Saraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kushal","family":"Garima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Dharwadkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Keshav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourabh D.","family":"Patwardhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh B.","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moneesh","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Phadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupriya","family":"Khare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avain","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-4606","authenticated-orcid":false,"given":"Sanjay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"1414_CR1","doi-asserted-by":"publisher","first-page":"e1175","DOI":"10.1016\/S2214-109X(25)00143-3","volume":"13","author":"YD Jeong","year":"2025","unstructured":"Jeong YD, Park S, Kim MS, et al. Global burden of vision impairment due to age-related macular degeneration, 1990\u20132021, with forecasts to 2050: a systematic analysis for the global burden of disease study 2021. Lancet Glob Health. 2025;13:e1175\u201390. https:\/\/doi.org\/10.1016\/S2214-109X(25)00143-3.","journal-title":"Lancet Glob Health"},{"key":"1414_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMcp2102061","volume":"385","author":"RS Apte","year":"2021","unstructured":"Apte RS. Age-related macular degeneration. N Engl J Med. 2021;385:539\u201347. https:\/\/doi.org\/10.1056\/NEJMcp2102061.","journal-title":"N Engl J Med"},{"key":"1414_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392:1147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(18)31550-2.","journal-title":"Lancet"},{"key":"1414_CR4","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"CATT Research group","year":"2011","unstructured":"CATT Research group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa1102673.","journal-title":"N Engl J Med"},{"key":"1414_CR5","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2012;119:1388\u201398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053.","journal-title":"Ophthalmology"},{"key":"1414_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.1","author":"FG Ahfat","year":"2013","unstructured":"Ahfat FG, Zaidi FH. Bevacizumab vs ranibizumab\u2014an appraisal of the evidence from CATT and IVAN. Eye. 2013. https:\/\/doi.org\/10.1038\/eye.2013.1.","journal-title":"Eye"},{"key":"1414_CR7","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","volume":"120","author":"L Kodjikian","year":"2013","unstructured":"Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120:2300\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2013.06.020.","journal-title":"Ophthalmology"},{"key":"1414_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","volume":"97","author":"I Krebs","year":"2013","unstructured":"Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:266\u201371. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302391.","journal-title":"Br J Ophthalmol"},{"key":"1414_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragad\u00f3ttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122:146\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.041.","journal-title":"Ophthalmology"},{"key":"1414_CR10","doi-asserted-by":"publisher","first-page":"e0153052","DOI":"10.1371\/journal.pone.0153052","volume":"11","author":"AME Schauwvlieghe","year":"2016","unstructured":"Schauwvlieghe AME, Dijkman G, Hooymans JM, et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD study. PLoS ONE. 2016;11:e0153052. https:\/\/doi.org\/10.1371\/journal.pone.0153052.","journal-title":"PLoS ONE"},{"key":"1414_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ophtha.2015.09.002","volume":"123","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2016;123:70\u20137. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.002.","journal-title":"Ophthalmology"},{"key":"1414_CR12","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3390\/ph17081000","volume":"17","author":"J Estarreja","year":"2024","unstructured":"Estarreja J, Mendes P, Silva C, Camacho P, Mateus V. Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis. Pharmaceuticals. 2024;17:1000. https:\/\/doi.org\/10.3390\/ph17081000.","journal-title":"Pharmaceuticals"},{"key":"1414_CR13","unstructured":"Kiss S. Perspectives on intravenous bevacizumab repackaged for intravitreal use. Mod Retina Summer. 2022. https:\/\/www.modernretina.com\/view\/perspectives-on-intravenous-bevacizumab-repackaged-for-intravitreal-use. Accessed 2 Jan 2026."},{"key":"1414_CR14","unstructured":"United States Pharmacopeia Convention. \u3008797\u3009 Pharmaceutical compounding\u2014sterile preparations. Rockville, MD. 2022. https:\/\/doi.usp.org\/USPNF\/USPNF_M99925_07_01.html. Accessed 2 Jan 2026."},{"key":"1414_CR15","unstructured":"United States Pharmacopeia Convention. \u3008789\u3009 Particulate matter in ophthalmic solutions. Rockville, MD. 2023. https:\/\/doi.usp.org\/USPNF\/USPNF_M99587_01_01.html. Accessed 23 Jan 2026."},{"key":"1414_CR16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/eye.2013.139","volume":"27","author":"JM Palmer","year":"2013","unstructured":"Palmer JM, Amoaku WM, Kamali F. Quality of bevacizumab compounded for intravitreal administration. Eye. 2013;27:1090\u20137. https:\/\/doi.org\/10.1038\/eye.2013.139.","journal-title":"Eye"},{"key":"1414_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaophthalmol.2014.3591","volume":"133","author":"NA Yannuzzi","year":"2015","unstructured":"Yannuzzi NA, Klufas MA, Quach L, et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 2015;133:32. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.3591.","journal-title":"JAMA Ophthalmol"},{"key":"1414_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1089\/jop.2019.0042","volume":"35","author":"M Crul","year":"2019","unstructured":"Crul M, Zandvliet A, Moes JR, Veenbaas T, Smeets O. Bevacizumab for intravitreal injection: impact of sub-visible particles on the shelf-life of repackaged bevacizumab. J Ocul Pharmacol Ther. 2019;35:372\u20135. https:\/\/doi.org\/10.1089\/jop.2019.0042.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1414_CR19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2147\/OPTH.S207978","volume":"14","author":"M Schargus","year":"2020","unstructured":"Schargus M, Frings A. Issues with intravitreal administration of anti-VEGF drugs. Clin Ophthalmol. 2020;14:897\u2013904. https:\/\/doi.org\/10.2147\/OPTH.S207978.","journal-title":"Clin Ophthalmol"},{"key":"1414_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/ICB.0000000000000570","volume":"13","author":"RL Avery","year":"2019","unstructured":"Avery RL, Castellarin AA, Dhoot DS, et al. Large silicone droplets after intravitreal bevacizumab (AVASTIN). Retin Cases Brief Rep. 2019;13:130\u20134. https:\/\/doi.org\/10.1097\/ICB.0000000000000570.","journal-title":"Retin Cases Brief Rep"},{"key":"1414_CR21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/IAE.0000000000002947","volume":"41","author":"SM Dounce","year":"2021","unstructured":"Dounce SM, Laskina O, Goldberg RA. Particulate matter from syringes used for intravitreal injections. Retina. 2021;41:827\u201333. https:\/\/doi.org\/10.1097\/IAE.0000000000002947.","journal-title":"Retina"},{"key":"1414_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.4103\/ijo.IJO_24_20","volume":"68","author":"R Narayanan","year":"2020","unstructured":"Narayanan R. Commentary: single-use Bevacizumab: the final solution? Indian J Ophthalmol. 2020;68:1102. https:\/\/doi.org\/10.4103\/ijo.IJO_24_20.","journal-title":"Indian J Ophthalmol"},{"key":"1414_CR23","unstructured":"United States Pharmacopeia Convention. \u3008787\u3009 Subvisible particulate matter in therapeutic protein injections. Rockville, MD. 2020. https:\/\/doi.usp.org\/USPNF\/USPNF_M6497_02_01.html. Accessed 23 Jan 2026."},{"key":"1414_CR24","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636\u201341. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305252.","journal-title":"Br J Ophthalmol"},{"key":"1414_CR25","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab and ranibizumab. Retina. 2017;37:1847\u201358. https:\/\/doi.org\/10.1097\/IAE.0000000000001493.","journal-title":"Retina"},{"key":"1414_CR26","doi-asserted-by":"publisher","first-page":"e000764","DOI":"10.1136\/bmjophth-2021-000764","volume":"6","author":"MS Sivertsen","year":"2021","unstructured":"Sivertsen MS, Lode HE, Gj\u00f8lberg TT, et al. Cluster of symptomatic silicone oil droplets following intravitreal injections: a 1-year observational study. BMJ Open Ophthalmol. 2021;6:e000764. https:\/\/doi.org\/10.1136\/bmjophth-2021-000764.","journal-title":"BMJ Open Ophthalmol"},{"key":"1414_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1177\/1120672118823133","volume":"30","author":"JL Olea","year":"2020","unstructured":"Olea JL, G\u00f3mez-Resa M, Cervera-Peris MM, Arag\u00f3n JA. Silicone oil droplets in repackaged anti-vascular endothelial growth factors for intravitreal injections: in search of the main source of contamination. Eur J Ophthalmol. 2020;30:774\u20139. https:\/\/doi.org\/10.1177\/1120672118823133.","journal-title":"Eur J Ophthalmol"},{"key":"1414_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ajo.2011.11.023","volume":"153","author":"S Gonzalez","year":"2012","unstructured":"Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn\u2019t blind people, people blind people. Am J Ophthalmol. 2012;153:196\u2013203. https:\/\/doi.org\/10.1016\/j.ajo.2011.11.023.","journal-title":"Am J Ophthalmol"},{"key":"1414_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/eye.2009.86","volume":"24","author":"SH Lee","year":"2010","unstructured":"Lee SH, Woo SJ, Park KH, et al. Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Eye. 2010;24:226\u201332. https:\/\/doi.org\/10.1038\/eye.2009.86.","journal-title":"Eye"},{"key":"1414_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s10792-024-03134-5","volume":"44","author":"U Kivrak","year":"2024","unstructured":"Kivrak U, Arsan AK, Ak\u00e7ay G, et al. Clinical features, management, and outcomes of patients with sterile endophthalmitis associated with intravitreal bevacizumab injection: retrospective case series. Int Ophthalmol. 2024;44:216. https:\/\/doi.org\/10.1007\/s10792-024-03134-5.","journal-title":"Int Ophthalmol"},{"key":"1414_CR31","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S66230","author":"R Velez-Montoya","year":"2014","unstructured":"Velez-Montoya R, Ortega-Larrocea X, Orozco-Hernandez A, Sanchez-Bermudez G, Morales-Canton V, Garcia-Aguirre G. Acute sterile endophthalmitis following intravitreal bevacizumab: case series. Clin Ophthalmol. 2014. https:\/\/doi.org\/10.2147\/OPTH.S66230.","journal-title":"Clin Ophthalmol"},{"key":"1414_CR32","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/bjophthalmol-2018-313131","volume":"103","author":"AK Agarwal","year":"2019","unstructured":"Agarwal AK, Aggarwal K, Samanta R, et al. Cluster endophthalmitis due to Stenotrophomonas maltophilia following intravitreal bevacizumab: outcomes of patients from North India. Br J Ophthalmol. 2019;103:1278\u201383. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313131.","journal-title":"Br J Ophthalmol"},{"key":"1414_CR33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.4103\/0301-4738.99855","volume":"64","author":"P Khan","year":"2016","unstructured":"Khan P, Khan L, Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2016;64:694. https:\/\/doi.org\/10.4103\/0301-4738.99855.","journal-title":"Indian J Ophthalmol"},{"key":"1414_CR34","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.oret.2020.12.020","volume":"5","author":"W Song","year":"2021","unstructured":"Song W, Singh RP, Rachitskaya AV. The effect of delay in care among patients requiring intravitreal injections. Ophthalmol Retina. 2021;5:975\u201380. https:\/\/doi.org\/10.1016\/j.oret.2020.12.020.","journal-title":"Ophthalmol Retina"},{"key":"1414_CR35","unstructured":"Roche Pharma AG. Summary of product characteristics: Avastin\u00ae (Bevacizumab). 2006. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avastin."},{"key":"1414_CR36","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s40123-024-01002-0","volume":"13","author":"J Uzzan","year":"2024","unstructured":"Uzzan J, Mapani A, Cox O, Bagijn M, Saffar I. Clinical outcomes and experiences with prefilled syringes versus vials for intravitreal administration of anti-VEGF treatments: a systematic review. Ophthalmol Ther. 2024;13:2445\u201365. https:\/\/doi.org\/10.1007\/s40123-024-01002-0.","journal-title":"Ophthalmol Ther"},{"key":"1414_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.5301\/ejo.5000629","volume":"25","author":"E Souied","year":"2015","unstructured":"Souied E, Nghiem-Buffet S, Leteneux C, et al. Ranibizumab prefilled syringes: benefits of reduced syringe preparation times and less complex preparation procedures. Eur J Ophthalmol. 2015;25:529\u201334. https:\/\/doi.org\/10.5301\/ejo.5000629.","journal-title":"Eur J Ophthalmol"},{"key":"1414_CR38","first-page":"A5214","volume":"63","author":"Y Subhi","year":"2016","unstructured":"Subhi Y, Kjer B, Munch IC. Prefilled syringes for intravitreal injection reduce preparation time. Dan Med J. 2016;63:A5214.","journal-title":"Dan Med J"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01414-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01414-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01414-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:26:20Z","timestamp":1782739580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01414-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01414-0","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sandhya Dharwadkar, Satish Keshav, Sourabh D. Patwardhan, Nilesh B. Giri, Moneesh Saxena and Vinod Kumar were the study investigators, received grants\/investigator fees from the Gennova Biopharmaceuticals Limited for conducting the study at their respective sites. Anupriya Khare and Avain Mishra are employees of the Clinical Research Network India, the Contract Research Organization who managed the study on behalf of Gennova Biopharmaceuticals Limited. Amit Saraf, Kushal Garima, Yogesh Phadke and Sanjay Singh are employees of Gennova Biopharmaceuticals Limited. The authors declare that they have no other conflicts of interest relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki 1964 and its later amendments, International Conference on Harmonization- Good Clinical Practice (ICH-GCP), as well as applicable regulatory requirements. The central licensing authority (Central Drugs Standard Control Organisation) and institutional ethics committee at each site approved the study prior to its initiation. A list of study sites and their respective ethics committees is provided in the Supplementary Material (Table\u00a0\n                      \n                      ). All participants provided written informed consent before enrolment in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}